The Nevada Cancer Research Foundation (NCRF) was established in 1983 to conduct cancer research. The NCRF main office is located in central Las Vegas with satellite offices In Reno and Carson City, Nevada. Over 90% of the oncologists, hematologists and radiation oncologists in Nevada are investigator members of the NCRF and participate in NCI clinical trials and projects. NCRF's mission is to provide quality and state-of-the-art treatment in Nevada through participation in active research in cancer prevention, cancer screening, post-treatment surveillance, cancer control, cancer care delivery, Imaging, cancer treatment, health-related quality of life studies, correlative science sub-studies biospecimen collection, and cancer disparities to the citizens of Nevada through the participation of the local physicians and health care providers. NCRF also has as part of Its mission the provision of high quality, timely data to the NCI Community Oncology Research Program (NCORP) Research Bases in a research environment that sets the highest standards for the safety and welfare of the clinical trials'participants. NCRF will continue to enroll patients/participants on NCI clinical trials, plans to meet and exceed the minimum enrollment of 40 patients/participants annually evenly distributed over the available cancer prevention, control, screening, and post-treatment surveillance clinical trials, and to meet and exceed the minimum enrollment of 40 patients/participants to treatment and imaging clinical trials that is required for participation in NCORP. NCRF plans to actively work with the NCI to develop an integrated community-based research network in order to reduce the cancer incidence, morbidity, and mortality in Nevada by accelerating the transfer of newly developed cancer prevention, early detection, treatment, patient management rehabilitation, quality of life, and continuing care technology. NCRF will involve NCRF staff and physicians in the scientific and educational activities of the Research Bases and will participate in studies to enhance participation of racial/ethnic and other underserved populations underrepresented In research. To accomplish these goals, the NCRF opens the program for state-wide participation, thereby providing access for participation to the citizens of Nevada.
This state-wide program provides access to research in cancer prevention, cancer screening, post-treatment surveillance, cancer control, cancer care deliver, imaging, cancer treatment, health-related quality of life studies, correlative science su-studies biospecimen collection, and cancer disparities to all interested professionals from varied medical and academic disciplines for state-wide participation, thereby providing access for participation to the citizens of Nevada.
|Kyriakopoulos, Christos E; Chen, Yu-Hui; Carducci, Michael A et al. (2018) Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol 36:1080-1087|
|Gravis, Gwenaelle; Boher, Jean-Marie; Chen, Yu-Hui et al. (2018) Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol 73:847-855|
|Harshman, Lauren C; Chen, Yu-Hui; Liu, Glenn et al. (2018) Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. J Clin Oncol 36:376-382|
|Henry, N Lynn; Unger, Joseph M; Schott, Anne F et al. (2018) Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol 36:326-332|
|Flaig, Thomas W; Plets, Melissa; Hussain, Maha H A et al. (2017) Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. JAMA Oncol 3:e170231|
|Yao, James C; Guthrie, Katherine A; Moran, Cesar et al. (2017) Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol 35:1695-1703|
|Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050|
|Durie, Brian G M; Hoering, Antje; Abidi, Muneer H et al. (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519-527|
|Enzinger, Peter C; Burtness, Barbara Ann; Niedzwiecki, Donna et al. (2016) CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. J Clin Oncol 34:2736-42|
|Sweeney, Christopher J; Chen, Yu-Hui; Carducci, Michael et al. (2015) Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med 373:737-46|